Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Meaning-centred group psychotherapy for cancer survivors effective in the long run

08 Mar 2020
Psychotherapy not only helps to alleviate symptoms, but also allows patients to develop inner capacities and resources that lead to a more fulfilling life.

Meaning-centred group psychotherapy for cancer survivors (MCGP-CS) has lasting benefits on participants’ sense of personal growth and on their positive relations with other people, reports a new study.

Researchers randomly assigned 170 cancer survivors to MCGP-CS, supportive group psychotherapy or care as usual (CAU). Study outcomes included scores in the Personal Meaning Profile (PMP), Ryff’s Scales of Psychological Well-Being (SPWB) and the Posttraumatic Growth Inventory. Assessments were performed at baseline and at 1 week, 3 months, 6 months, 1 year and 2 years after the intervention.

Breast cancer was the most common malignancy. Most participants had completed their main treatments 1.5 years prior, and almost half were still on hormonal therapy. Thirteen patients experienced cancer recurrence during follow-up while three died.

Total scores in the PMP and SPWB scales showed no significant between-group long-term difference, with scores remaining comparable from baseline to 2 years follow-up.

However, researchers detected significantly stronger long-term effects of MCGP-CS compared to CAU in terms of goal-orientedness (p<0.001) and positive relations (p=0.025).

At baseline, Cohen’s d effect sizes showed a significant and large advantage of MCGP-CS over CAU in terms of goal-orientedness (p<0.001), though this was attenuated over time. The effect size difference between MCGP-CS and CAU remained medium to large over the long term in terms of positive relations.

The principal findings were robust to sensitivity analyses and remained stable even when excluding participants who had received psychological treatment from 4 weeks before the study to 2 years after.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.